Copper orotate | 61573-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Copper orotate
• 英文别名: copper;2,4-dioxo-1H-pyrimidine-6-carboxylate
• CAS: 61573-60-2
• 化学式: C10H6CuN4O8
• 分子量: 373.72
• InChiKey: WKQFGWKSVRJAMI-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -5.15
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  197
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Pharmaceutical formulations for the oral delivery of peptide drugs
  申请人：Cyprumed GmbH

  公开号：US10905744B2

  公开（公告）日：2021-02-02

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

  本发明涉及肽类药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于 5 kDa 的多肽药物，可用作药物，其中所述多肽药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物以及药学上可接受的络合剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于 5 kDa 的多肽药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物；以及药学上可接受的络合剂。
• Treatment for depression and depressive disorders
  申请人：Medlab IP Pty Ltd

  公开号：US11135181B2

  公开（公告）日：2021-10-05

  Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of one or more probiotic microorganisms, or administration of a combination of orotic acid or a salt thereof and one or more probiotic microorganisms.

  本文提供了用于治疗抑郁、焦虑或抑郁或焦虑相关疾病的方法和组合物。本发明的实施方案描述了奥罗酸或其盐的施用，或一种或多种益生微生物的施用，或奥罗酸或其盐与一种或多种益生微生物的组合施用。
• Copper chelation therapeutics
  申请人：Bermudes David Gordon

  公开号：US11471497B1

  公开（公告）日：2022-10-18

  Bacterial strains are provided having at least one enhanced mechanism to sequester, bind, precipitate, chemically oxidize or reduce copper ions or other toxic divalent transition metals. The bacteria may also have optional copper resistance mechanisms. The bacteria reduce the amount of available copper to tissues, which may be cancerous tissues, and reduce tumor growth, angiogenesis and/or metastasis, or tissues subject to excess copper due to host defects in copper metabolism. The bacteria are useful for treatment of neoplastic diseases including solid tumors and lymphomas, as well as Wilson's Disease, Menke's Disease, and possible Alzheimer's Disease, Parkinson's Disease, and Creutzfeldt-Jakob Disease.

  所提供的细菌菌株至少具有一种增强的机制，可固着、结合、沉淀、化学氧化或还原铜离子或其他有毒的二价过渡金属。细菌还可能具有可选的抗铜机制。这些细菌可减少组织（可能是癌组织）的可用铜量，并减少肿瘤生长、血管生成和/或转移，或减少因宿主铜代谢缺陷而导致铜过量的组织。这种细菌可用于治疗肿瘤性疾病，包括实体瘤和淋巴瘤，以及威尔逊氏病、门克氏病、可能的阿尔茨海默氏病、帕金森氏病和克雅氏病。
• Pharmaceutical compositions and their use in the treatment of neoplastic disease
  申请人：Carter John

  公开号：US20050123623A1

  公开（公告）日：2005-06-09

  A pharmaceutical composition is provided comprised of a physiologically acceptable source of assimilable copper, a source of salicylic acid or a physiologically acceptable derivative thereof, and vitamin C.

  一种药物组合物由生理上可接受的可同化铜源、水杨酸源或其生理上可接受的衍生物以及维生素 C 组成。
• PHARMACEUTICAL COMPOSITIONS CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C
  申请人：Carter, John

  公开号：EP1220678B1

  公开（公告）日：2007-03-07